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Ian TomlinsonAbstract
The intestinal polyposis syndromes are characterised by multiple polyps
of the large bowel, increased risk of colorectal cancer and a variety of
extra-colonic manifestations. Most are caused by high-penetrance germ-
line mutations in genes that affect signalling pathways (Wnt, BMP or
mTOR) or the repair of base substitution mutations. However, there are
exceptions to these rules: Lynch syndrome usually presents with few
polyps; and hyperplastic (serrated) polyposis currently has no known ge-
netic cause. Polyp morphology also varies considerably between, and
sometimes within, syndromes. Patients with the same germline mutations
can have very different disease severities and features, perhaps as a
result of modifying genes or simply chance. Although clinical features
and histopathology will continue to have an important role, molecular
testing is best placed to classify these diseases and hence inform patient
management. As more genes are identified, this classification is likely to
improve and enable better individual cancer prevention based on the
mutated gene, the specific germline mutation, modifier genes and non-
genetic factors.
Keywords colorectal cancer; DNA repair; genetics; polyposis; Wnt and
BMP signalling
Introduction
The colorectal polyp is accepted as being the precursor lesion for
most cancers of the large intestine. These polyps usually take the
form of conventional adenomas or a variety of lesions with
serrated morphology, some of which take a sessile form. How-
ever, there also exist a small number of rare, inherited conditions
in which there is a primary, high-penetrance predisposition to
intestinal polyps caused by a single faulty gene. In some of these
polyposis syndromes, the primary predisposition is to conven-
tional adenomas and in others it is to serrated lesions, yet in
other inherited polyposes, polyps are seen that very rarely have
any counterpart in the general population. Furthermore, in most
of the polyposis syndromes, polyps are not confined to the large
bowel, and there also often exist specific extra-intestinal features
that can help in the diagnosis of these conditions. Almost without
exception, the risk of colorectal carcinoma is increased in the
polyposis syndromes, but the risk of other specific extra-colonic
cancers is also raised in most cases, albeit rarely to a lifetime risk
as high as that of colorectal cancer.Ian Tomlinson PhD FRCPath is Professor of Molecular and Population
Genetics at the University of Oxford and Honorary Consultant in Clinical
Genetics, Oxford University Hospitals NHS Trust, UK.
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DIAGNOSTIC HISTOPATHOLOGY 21:4 147In this short review, I shall take a tour through the molecular
pathology of the major, known polyposis syndromes (Table 1),
focussing on recent new findings.Familial adenomatous polyposis (FAP)
FAP is caused by germline mutations in the APC gene (chro-
mosome 5p22.1) which encodes a protein with a major isoform
of 2843 amino acids. The protein is multi-functional, but its main
role seem to be to provide a scaffold for the phosphorylation of
the Wnt pathway effector, b-catenin which is subsequently
degraded.1 With very few exceptions, pathogenic APC mutations
are protein-truncating or -ablating mutations that disrupt the
scaffold. The great majority of pathogenic mutations occur before
codon 1580, and thereby remove critical “SAMP” repeats that
bind b-catenin. Simple base substitution mutations are almost all
non-pathogenic, although splice-site mutations can be. Classical
FAP is a disease of 100se1000s of adenomatous polyps
throughout the colorectum, although an attenuated disease
variant e caused by germline mutations in the ends of the gene
or the alternatively spliced exon 9 e also exist and patients
develop fewer polyps, typically 10e100. In addition, there exist
more subtle associations between polyp burden and APC muta-
tion location.2 As well as colorectal adenomas and CRC, FAP
patients are at increased risk of duodenal polyps and carcinoma,
gastric polyps, intra-abdominal desmoids and congenital hyper-
trophy of the retinal pigment epithelium (CHRPE), and also have
modestly increased risks of thyroid cancer, hepatoblastoma,
adrenocortical carcinoma and brain tumours.
APC is a prototypical tumour suppressor gene and FAP polyps
generally start to grow after “second hits” inactivate the wildtype
allele,3 although many FAP polyps are polyclonal, comprising
cells with different, independent second hits.4 The APC muta-
tions are thought to provide a very modest selective advantage to
the adenoma cell, but this is sufficient to cause thousands of
polyps given the huge number of crypts in the colorectum.5
Hundreds or more adenomas generally occur in the teens, but
few progress to CRC before the age of 30. In most cases, colec-
tomy or more extensive surgery is required to control the disease,
but this leaves considerable morbidity and risk of death from
duodenal carcinoma or desmoid disease.6
Despite the hypothetical constitutive Wnt activation that
bi-allelic inactivation of APC causes, the level of b-catenin in FAP
polyps is not always obviously raised and the protein is not
always present in the nucleus where it can effect transcription.7
Although the epithelium is APC-mutant, it is possible that the
wildtype mesenchyme can partly constrain the growth of FAP
polyps through production of homoeostatic growth signals, or
that the Wnt increase potentially delivered by APC mutation is
buffered by cell-intrinsic mechanisms. Nonetheless, when CRCs
occur in FAP, they have generally followed a classical pathway in
which APCmutations are followed by mutations in genes such as
KRAS, SMAD4 and TP53, probably accompanied by a grossly
abnormal chromosome complement (CIN).
The major remaining scientific and clinical challenges in FAP
include gaining a full understanding of how APC mutations
cause tumours, especially whether functional consequences
other than Wnt activation are important, and developing effec-
tive therapies against desmoids, which are benign, yet very 2015 The Author. Published by Elsevier Ltd. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
A summary of the colorectal polyposis syndromes
Condition Gene Colonic features Extra-colonic features Polyp morphology Mechanism
Familial adenomatous
polyposis (FAP)
APC Multiple polyps,
carcinoma
Duodenal polyps and
cancer, gastric polyps,
intra-abdominal desmoids,
Gardners’, CHRPE, thyroid
cancer, hepatoblastoma
Classical adenoma Wnt activation
MUYTH-associated
polyposis (MAP)
MUYTH Multiple polyps,
carcinoma
Duodenal polyps and cancer,
gastric polyps
Classical adenoma
Possibly serrated polyps
Defective base
excision repair
Polymerase
proofreading-associated
polyposis (PPAP)
POLE
POLD1
Multiple polyps,
carcinoma
Duodenal polyps and cancer,
endometrial cancer, possibly
other cancers
Classical adenoma Defective polymerase
proofreading repair
Juvenile polyposis (JPS) SMAD4
BMPR1A
Multiple polyps,
carcinoma
Duodenal polyps, gastric
polyps. AV malformations
with SMAD4 mutations
Juvenile-type
(smooth, lobulated,
cystic)
BMP inhibition
Hereditary Mixed
Polyposis (HMPS)
GREM1 Multiple polyps,
carcinoma
None known Several different types
and mixed morphology
Hyperplastic polyps and
serrated adenomas
predominate
BMP inhibition
Cowden syndrome (CS) PTEN Multiple polyps
Carcinoma risk
unclear
Many Hamartomas, juvenile-like AKT activation
PeutzeJeghers syndrome
(PJS)
LKB1 (STK11) Multiple polyps,
carcinoma
Polyps elsewhere in
gastrointestinal tract
Risk of several other cancer
types
“Freckling” of lips, buccal
mucosa and other skin sites
PJS-type (arborizing,
smooth muscle core)
mTOR activation
Hyperplastic polyposis
(HPPS)
Not known Multiple polyps,
carcinoma
None known Hyperplastic polyps
(often large, proximal colon),
serrated and conventional
adenomas
Not known
Multiple adenomas (MAs) Not known
Polygenic in
some cases
Multiple polyps,
carcinoma
None known Classical adenomas, sometimes
with serrated lesions
Not known
Table 1
MINI-SYMPOSIUM: PATHOLOGY OF HEREDITARY GASTROINTESTINAL NEOPLASIAdifficult to eradicate with surgery, and the cause of very
dangerous side-effects owing to their size and effects on nearby
organs.
DNA repair deficiencies: Lynch syndrome, polymerase
proofreading-associated polyposis and MUTYH-associated
polyposis
These conditions have related causes in a compromised ability to
repair mispaired bases or small insertion-deletion mutations,
often arising from DNA replication errors. Lynch syndrome (LS)
results from defective DNA mismatch repair (MMR). A germline
MMR mutation in MSH2 (chromosome 2p21, including deletions
overlapping with the EPCAM gene), MLH1 (chromosome
3p21.3), MSH6 (chromosome 2p16.3) or PMS2 (chromosome
7p22.1) causes MMR inactivation once a second hit occurs. LS is
typified by CRC, endometrial cancer and lower, risks of otherDIAGNOSTIC HISTOPATHOLOGY 21:4 148cancers (gastric, ovarian, skin (MuireTorre syndrome), small
bowel, uroepithelial, and others),8 but usually there is no true
polyposis; however, a few LS patients do develop multiple
serrated polyps or adenomas,9 for reasons that are not well un-
derstood, but may include the action of modifying genes. MMR
acts after normal DNA replication to “mop up” spontaneous
mutations that have eluded other repair mechanisms after a cell
replicates its DNA. It is relatively more effective against small
insertions or deletions, and here its loss causes the phenomenon
of “microsatellite instability” (MSI) in short repeat tracts. It
has been shown that the colons of LS patients contain multiple
crypts that have lost MMR after second hits, but e in contrast to
FAP e these crypts do not generally turn into a tumour and LS
cases overall have a very modest excess of polyps.10 However,
when tumorigenesis does occur, it appears to be very rapid in LS,
with endoscopically-visible lesions having a short life before
progression, again in contrast to FAP. 2015 The Author. Published by Elsevier Ltd. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
MINI-SYMPOSIUM: PATHOLOGY OF HEREDITARY GASTROINTESTINAL NEOPLASIAPolymerase proofreading-associated polyposis (PPAP) is a
recently described, autosomal dominant condition that is func-
tionally related to LS. The defect in PPAP is in the first stage
(prior to MMR acting) in correcting errors from DNA replication.
The major DNA polymerases ( 3 and d) have a polymerase
domain, and a proof-reading (exonuclease) domain, and PPAP
patients have defects in the latter that cause a massive accu-
mulation of base substitution mutations. Specific, germline
missense mutations in the POLE (chromosome 12q24.33) and
POLD1 (chromosome 19q13.33) genes cause proof-reading defi-
ciency and tumorigenesis.11 The PPAP phenotype is like LS in its
tumour spectrum, but often with multiple colorectal adenomas
(like attenuated polyposis) and usually without MSI. PPAP can-
cers seem not to have second hits at POLE or POLD1, and are
thought to have acquired millions of mutations.
MUTYH-associated polyposis (MAP) is unusual in the polyp-
osis syndromes in that it is inherited as a recessive trait. It was
discovered when researchers were investigating patients with a
phenotype very like attenuated FAP. The polyps of the patients
being studied had no identifiable germline cause for their disease,
but the somatic APC mutation spectrum was unusually biased
towards G:C > T:A changes, indicating a defect in DNA base
excision repair. Bi-allelic mutations in MUTYH, a gene that en-
codes a DNA glycosylase involved in fixing oxidative damage by
base excision repair, were found in the patients.12 Very recently,
consanguineous individuals with a phenotype resembling LS,
MAP and PPAP have been reported to carry homozygous inacti-
vating germline mutations in another base excision repair gene,
NTHL1. The pathogenesis of these tumours is likely to result from
similar mechanisms to those in MAP.29
Furthermore, there exists a very rare set of patients with bi-
allelic germline mutations in the MMR genes. These individuals
have “congenital MMR deficiency” (CMMRD), and often present
with early-onset brain tumours or leukaemias. However, a small
number of patients have multiple colorectal adenomas. Para-
doxically, CMMRD tumours are oftenMSI-negative, but colorectal
adenomas appear to be able to readily progress to cancer, themost
severely affected individual in the literature having a total of 10
CRCs at age 23.13 Interestingly, brain tumours in CMMRD patients
seem to develop by acquiring very similar POLE and POLD1
mutations to those found in PPAP, rather than directly through
MMR deficiency.14
There is currently little indication as to why different, yet
functionally related, forms of DNA repair defect confer over-
lapping, but distinct, phenotypes and different modes of inheri-
tance. There are some clues. For example, it is suspected that the
MMR mutations in CMMRD do not cause severe constitutional
loss of MMR capability, or they would be developmentally lethal,
but why they do not cause MSI is very unclear. One possibility is
that they actually have only partial MMR loss, as evidenced by
the preponderance of PMS2 and MSH6 mutations in these cases,
rather than the MSH2 and MLH1 mutations more typical of LS.
The hamartomatous polyposis syndromes: juvenile polyposis,
hereditary mixed polyposis, Cowden syndrome and Peutz
eJeghers disease
Hamartomas are classically an excess of normal tissue, although
it is not clear that this classification is appropriate for theDIAGNOSTIC HISTOPATHOLOGY 21:4 149hamartomatous polyposes except inasmuch as the polyps are
mostly non-dysplastic. In all the above cases, it remains uncer-
tain whether these lesions arise from clonal expansion of a single
cell or few cells, or whether they are the offspring of multiple
cells. It is also debated whether these genes act as tumour sup-
pressors (with inactivation of the germline wildtype allele in
polyps) and even whether the underlying defect is in the
epithelium or mesenchyme. However, it is clear that juvenile
polyposis (JPS) and PeutzeJeghers syndrome (PJS), at least, are
associated with a greatly increased risk of colorectal carcinoma.
All the hamartomatous polyposes are dominantly inherited
conditions and they often present in childhood.
JPS polyps are classically smooth and lobulated, with a cystic
appearance and predominant stroma. They can occur throughout
the gastrointestinal tract and can cause cancers of the stomach,
small bowel and colorectum. The cancer risk per polyp is prob-
ably higher than in FAP. Germline mutations in two genes,
SMAD4 (chromosome 18q21) and BMPR1A (chromosome
10q23.2), can cause JPS.15,16 Patients usually present with a
mixture of juvenile and adenomatous polyps. SMAD4 mutations
are associated with more severe upper gastrointestinal disease17
and, in some families, with arterio-venous malformations that
can result in hereditary haemorrhagic telangiectasia.18 Both
SMAD4 and BMPR1A act in the bone morphogenetic protein
signalling (BMP) pathway, which is related to the TGF-beta
pathway. BMP signalling is thought to be a pro-differentiation
force in the normal intestinal crypt, and its attenuation by
germline mutation may favour proliferation and/or a stem cell
phenotype.19
Hereditary mixed polyposis syndrome (HMPS) results from
another germline BMP pathway defect, specifically over-
expression of the secreted BMP antagonist GREM1. The HMPS
mutation appears to have arisen from a single ancestor and to
date HMPS has only been reported in individuals of Ashkenazi
Jewish descent. The actual mutation is an unusual 40 kb dupli-
cation upstream of GREM1 (chromosome 15q13.3) which causes
the protein to be produced not only in the crypt mesenchyme, but
also in the epithelium.20 HMPS polyps can resemble hyper-
plastic/serrated lesions, conventional adenomas or juvenile
polyps, with multiple morphologies often present in the same
lesion. Uniquely among the Mendelian CRC syndromes, HMPS
has no known extra-colonic features.
Cowden syndrome (CS), and its variants LhermitteeDuclos
and BannayaneZonanaeRileyeRuvalcabaeMyhreeSmith syn-
dromes, is sometimes termed the multiple hamartoma syndrome.
It is a complex disorder with many variable features, including
polyps of the large bowel that resemble juvenile polyps and
increased breast, thyroid and endometrial cancer risk. It is very
unusual for CS to present with bowel polyps alone and the risk of
bowel cancer in CS cases is also uncertain.21 The genetics of CS
are no less confusing and controversial, but it is firmly estab-
lished that germline PTENmutations are the major cause.22 PTEN
(chromosome 10q23.3) normally acts to repress Pi3 kinase and
AKT signalling.
PJS has features that, aside from a greatly raised colorectal
cancer risk and dominant inheritance, overlap minimally with
those of the other Mendelian CRC syndromes. PJS polyps can
occur throughout the gastrointestinal tract and even in other
epithelia, such as the nose. They are classically arborizing lesions 2015 The Author. Published by Elsevier Ltd. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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have a greatly increased risk of CRC, but also have raised risks of
cancers of many other sites, including the stomach, breast,
pancreas, gall bladder and endometrium.23 The other classical
feature of PJS is pigmentation of the lips, buccal mucosa and
often other skins areas: these lesions resemble dark freckles and
are said to result from a failure to transfer melanin from mela-
nocytes to keratinocytes. The pigmentation in PJS tends to fade
with age, can be very variable in severity, and can resemble
several other syndromes that are not associated with increased
cancer risk. The PJS gene (STK11, otherwise known as LKB1)
maps to chromosome 19p13.3 and encodes a protein that acts in
the mTOR signalling pathway.24,25 It is probably is an upstream
kinase of the major energy sensor AMPK, and the mechanism of
action of LKB1 mutations, whilst largely unclear, seem different
from any of the other polyposis genes.
Diagnosis of the Mendelian polyposis syndromes
The availability of rapid, sensitive and specific methods of DNA
sequencing mean that the classification of the polyposis syn-
dromes is now primarily molecular. Screening panels for all the
genes described above are available and are being introduced
into clinical practice. Occasionally, where there is excellent
clinical and family history evidence, and where the mutation
spectrum is restricted, focussed screening can be performed first.
For example, an Ashkenazi individual with a dominant family
history and polyps with mixed morphology can be screened for
HMPS using a single polymerase chain reaction (PCR); and MAP
can be rapidly screened using one or two PCR reactions for the
most common mutations in specific ethnic groups. However,
these methods are slowly being displaced, especially as we come
to realise that most inherited cancer syndromes confer not only
very high risks of some cancers, but also small increased risks of
several other cancer types.
Even where no mutation can be found, molecular methods
can be used to diagnose some polyposis syndromes. LS cancers
have MSI and often show loss of the MMR protein(s) on immu-
nohistochemistry; they can be distinguished from sporadic MSI þ
cancers by a lack of MLH1 methylation and, usually, absence of
BRAF mutation. These tests can also help to sort pathogenic
mutations from rare bystander mutations. Mutation burden and
spectrum tests in polyps can also be used in principle to diagnose
MAP and PPAP, although these tests are not routinely used in
clinical molecular practice.
There will remain some patients with occult mutations, or
mutations in undiscovered predisposition genes, who must be
classified using their clinical features, family history and histo-
pathology. The accuracy of this is likely to be highly variable. For
example, patients with thousands of colorectal adenomas, des-
moids and a dominant family history are likely to have FAP,
whereas those with arborizing polyps and buccal pigmentation
are likely to have PJS. However, other patients are much harder
to classify, as the following section shows.
The genetically uncharacterised polyposes: hyperplastic
polyposis syndrome and the multiple adenoma phenotype
Hyperplastic polyposis syndrome (HPPS, or serrated polyposis
syndrome) is a poorly defined condition with uncertainDIAGNOSTIC HISTOPATHOLOGY 21:4 150inheritance.26 At one extreme, there exist patients with tens of
hundreds of serrated polyps that present in their 20s or 20s and
who may also have CRC. Extra-colonic disease is rare and usually
there are few, if any, affected relatives. It is unclear whether this
condition is distinct from, or continuous with, the phenotype of
asymptomatic older patients found to have tens of small serrated
polyps, often in bowel cancer screening programmes. The defi-
nition of HPPS is evolving to take account of age, polyp sites and
burden, and the presence of CRC, but what is ultimately required
is a molecular classification.27 Unfortunately, with the exception
of a very few patients with germline MUTYH or GREM1 muta-
tions, HPPS predisposition genes have not been forthcoming
despite tens of patients having had exome sequencing for
germline mutations. Several potential explanations exist for this
failure (for example, occult mutations and even a non-genetic
aetiology). The HPPS phenotype may overlap with that of a
second group of patients with multiple colorectal adenomas
(MAs), but no mutations in the known Mendelian CRC genes.
MA patients too can present in the first 2 or 3 decades of life with
hundreds of conventional adenomas, CRC and often very limited
family history. As for HPPS, MA genes have in general not been
forthcoming in large sequencing projects, although PPAP and
NTHL1-associated polyposis were discovered in that way. It is
quite possible that both HPPS and MA are severely genetically
heterogeneous and that even larger sequencing efforts will be
needed to characterise them genetically. There is also some ev-
idence that some HPPS and MA cases represent individuals in the
tail of the normal distribution of common, low-risk CRC predis-
position polymorphisms.28
Concluding remarks
The polyposis syndromes are fascinating examples of how can-
cers can arise in a number of different settings. Polyp
morphology is shared across some syndromes (FAP, AFAP,
MAP, PPAP), but not others, the cancer risk is variable, and often
hard to estimate, and the presence of extra-colonic features dif-
fers among patients and genes. Most polyposis syndromes are
high-penetrance, Mendelian dominant conditions, with the
exception of MAP and NTHL1-associated polyposis, and perhaps,
HPPS. Most of these diseases can be detected in childhood, either
owing to a known family history, classical phenotype (for
example, FAP), or sometimes owing to unusual presentations
(such as intussusception or volvulus caused by polyps in PJS).
However, new cases of PPAP and MAP are more often detected
in adults. There are many molecular ways to cause a polyp,
including DNA repair deficiency and signalling pathway activa-
tion or abrogation, and identical phenotypes can be caused by
very different underlying defects, such as Wnt activation in FAP
and DNA repair problems in MAP and PPAP. Furthermore, it is
very unclear as to why the DNA repair defects involved in CRC
predisposition are principally those in which single base changes
are corrected. We also need to explain why LS does not usually
present with multiple polyps e in contrast to MAP, PPAP,
CMMRD and NTHL1-associated polyposis e although this is
likely in part to reflect the need for “second hits” to inactivate the
wildtype copy ofMSH2 andMLH1. Finally, it is now the case that
molecular testing is best placed to classify these diseases and
hence inform patient management. As time goes on, this 2015 The Author. Published by Elsevier Ltd. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
MINI-SYMPOSIUM: PATHOLOGY OF HEREDITARY GASTROINTESTINAL NEOPLASIAclassification will improve and enable cancer prevention mea-
sures increasingly to be tailored to individuals. A
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